Can Cannabis Be Considered a Substitute Medication for Alcohol?

Meenakshi Sabina Subbaraman

Disclosures

Alcohol Alcohol. 2014;49(3):292-298. 

In This Article

Results

Results are summarized in Table 1 . The first column states each criterion. The second column summarizes the studies for and against substitution. The third column states notable study design flaws for studies cited in column 2.

Criterion #1: It Should Reduce Alcohol Use and Related Harms

The earliest published account of cannabis substitution is a case study of a 49-year-old female alcoholic who found that with Antabuse and smoking cannabis helped her to quit drinking (Mikuriya, 1970). Within 5 months, the patient's physical and mental health markedly improved, and within 2 years, her liver and general health returned to normal. As her physician, Dr Mikuriya noted that although alcohol and cannabis differ greatly, they can both instill euphoria and detachment. But while alcohol seriously affected his patient physically and emotionally, cannabis did not produce the same negative consequences (Mikuriya, 1970). Mikuriya recommended clinical trials of cannabis among selected patients while cautioning that cannabis is not a panacea.

Mikuriya went on to lead two-additional cannabis substitution studies demonstrating cannabis' potential efficacy for both substitution and alleviation of alcohol-related harms. In a 2001 observational study, Mikuriya reviewed records from his medical practice and counted 104 patients who reported using cannabis to replace hazardous alcohol use. All of these patients claimed that cannabis relieved both craving for and symptoms masked by alcohol use (Mikuriya and Mandel, 2001). Most recently, another observational record review of 92 patients who substituted cannabis for alcohol showed that 100% reported cannabis as a very effective (50%) or effective (50%) substitute for alcohol. Ten percent of patients reported a year or more of alcohol abstinence and attributed their success to cannabis, while 21% reported return to unsafe drinking when stopping cannabis use (Mikuriya, 2004).

Mikuriya's studies suggest that cannabis substitution for alcohol can improve overall health (Mikuriya, 1970; Mikuriya and Mandel, 2001; Mikuriya, 2004), as well as alleviate pain resulting from alcohol-related injury in medical cannabis users (Mikuriya and Mandel, 2001). Importantly, the Mikuriya studies were observational and published in non-peer-reviewed journals, so the methodological rigor of the studies is not certain. Even so, reports from 1746 medical cannabis users in California corroborated that cannabis can alleviate anxiety and may help sleep (Reinarman et al., 2011). Similarly, data from the large (n = 43,093), nationally representative US National Epidemiologic Study on Alcohol and Related Conditions (NESARC) showed that 43% of those with a lifetime anxiety disorder self-medicated with alcohol (Bolton et al., 2009). Thus some individuals may use cannabis in similar contexts as alcohol.

Although the results from the above studies are provocative, they rely on retrospective designs and often focus on medical marijuana users without alcohol use disorders (AUD). Furthermore, medical marijuana patients may be dealing with illnesses that affect their drinking regardless of cannabis use. Peters and Hughes (2010) circumvented these study design problems by following 28 daily cannabis users who were not trying to reduce their cannabis consumption. Participants were asked to abstain from cannabis for 2 weeks; alcohol substitution occurred for participants with a past alcohol abuse or dependence diagnosis. The authors speculated that although cannabis and alcohol belong to different drug classes (i.e. cannabinoids versus sedatives) these participants were substituting 'pharmacologically similar' substances for one another in order to achieve similar effects (Peters and Hughes, 2010). A larger prospective study of 236 heavy drinkers similarly showed that cannabis users reduced alcohol consumption faster than non-users (Metrik et al., 2011).

Large, US nationally representative behavioral economics studies have reported that aggregate drinking may decrease if cannabis were legalized (Clements and Daryal, 2005), and that substitution is common in young adults (DiNardo and Lemieux, 2001). Results from the 2002–2007 National Survey of Drug Use and Health similarly showed that individual-level alcohol consumption increased and cannabis use significantly decreased at the minimum legal drinking age of 21, especially among women (Crost and Guerrero, 2012); the authors performed several sensitivity tests and concluded that alcohol and cannabis are substitutes, at least from an economic standpoint, and that the actual substitution effect is likely stronger than that shown due to potential under-reporting of cannabis use.

Conversely, other behavioral economic studies have found alcohol and cannabis to be complements in that the use of one substance increases use of the other (Bickel et al., 1995; Pacula, 1998; Moore, 2010). The discrepancies within behavioral economics imply that results from aggregate-level studies must be contextualized with individual-level studies. Furthermore, behavioral economic laboratory studies are conducted among individuals without AUD.

Although most of the above studies suggest that cannabis use can reduce alcohol use and related harms, many of the studies cited are limited by retrospective designs and selection bias. Furthermore, few focus on individuals with AUD. Findings from behavioral economics are mixed, with some calling cannabis and alcohol substitutes, and others calling them complements. Thus, cannabis only partially satisfies Criterion #1.

Criteria #2: It Should Ideally Be Free of Harms, or at Least Less Harmful Than Alcohol

Cannabis is certainly not free of harms (Room, 2006). However, two-independent groups of experts, including the British National Group of Consultant Psychiatrists registered on the Royal College of Psychiatrists as specialists in addiction, ranked cannabis as less harmful than both alcohol and benzodiazepines in terms of physical harm, dependence and social harm (i.e. accounting for factors such as toxicity and related health care costs; Nutt et al., 2007). Another possibly more objective comparison of harm may be the 'safety ratio' between the usual effective dose (for non-medical purposes) and the usual lethal dose: 10–20 for GHB and alcohol versus >100 for cannabis (Room, 2006). This again implies that cannabis may be safer than both alcohol and previously examined medication substitutes. Room (2006) also offered a short comparison of both individual and societal harms related to various psychoactive substances. He ranked alcohol, tobacco and cannabis as causing most to least harm. Specifically, he cited European studies that classify 'general toxicity' as very strong for alcohol and very weak for cannabis, and 'social dangerousness' as strong for alcohol and weak or none for cannabis.

Withdrawal from cannabis is also less severe than withdrawal from alcohol (and potentially benzodiazepines). Withdrawal from alcohol can lead to seizures or even death (Bayard et al., 2004). Similarly, withdrawal from benzodiazepines can lead to seizures or psychosis in extreme cases (Schweizer and Rickels, 1998). On the other hand, withdrawal from cannabis is much less severe, though it can lead to dysphoria or irritability (Budney et al., 2001). Although sometimes clinically ambiguous, cannabis withdrawal has been documented; a recently developed scale shows that cannabis withdrawal can correlate with trouble sleeping, nightmares/strange dreams and angry outbursts (Allsop et al., 2011, 2012).

Smoking cannabis, which is the most common way to ingest it, can lead to health problems such as impaired respiratory function. Furthermore, both incident and continued cannabis use have been linked to increased risk of incident psychotic symptoms (Kuepper et al., 2011), though cannabis use is not considered a sufficient cause for psychosis in itself (Arseneault et al., 2004). In sum, the above studies show that cannabis is safer than alcohol. Thus, cannabis satisfies the second criterion.

Criteria #3: Misuse Should Be Less Than That of Alcohol

Nutt et al. (2007) ranked both psychological and physical dependence risks for cannabis as lower than those for alcohol (Nutt et al., 2007). According to the US National Institute of Drug Abuse, 9% of those who use cannabis go on to develop dependence (US National Institute of Drug Abuse, 2013). On the other hand, NESARC results show that the lifetime prevalence of alcohol dependence is almost twice as high at 17.8% (Hasin et al., 2007). Among those with alcohol problems, a prevalence study of past 12-month alcohol use disorders showed that 9.9% of those with alcohol use disorders also had a cannabis use disorder (as defined by the diagnostic and statistical manual of mental disorders, 4th edition) compared with only 0.67% of those without alcohol use disorders (Stinson et al., 2006).

NESARC results also showed that approximately one-quarter of cannabis users also had an AUD. The co-use of other drugs was less common, ranging from ~9.5% for opioids to <1% for inhalant/solvent, heroin or other drugs. The rate of drug-specific substance use disorders was the highest for cannabis at ~10% (Falk et al., 2008). However, those with alcohol disorders also have higher rates of sedative misuse (Stinson et al., 2006), which highlights the importance of weighing criteria relative to alternatives like benzodiazepines.

Thus from a strictly epidemiological point of view, the documented rate of cannabis dependence is less than the rate of alcohol dependence, suggesting that cannabis may fulfill Criterion #3. However, the increased likelihood of cannabis dependence among those with past or current alcohol problems dampens support for this criterion.

Criterion #4: It Should Be Shown That It Can Substitute for Alcohol and Not Be Used Along With Alcohol

While some consider cannabis a complement to alcohol, a growing number of studies suggest that individuals actually substitute cannabis in place of alcohol. For example, 40% of 350 respondents reported substitution in a community-based survey of medical cannabis patients in Berkeley, CA, USA (Reiman, 2009). Although Reiman (2009) did not examine bivariate associations with past alcohol or drug treatment, 16% of participants reported formal substance abuse treatment and 2% reported involvement in a 12-step or other recovery program. In a similar study of 130 medical cannabis patients in the San Francisco Bay Area, half the sample reported using cannabis substitution for alcohol (Reiman, 2000). Within another community-based sample of medical marijuana patients in Canada (n = 404), 41% reported using cannabis as a substitute for alcohol (Lucas et al., 2012); rates of substitution were very similar to those reported in Reiman (2009). A 30-year-prospective study that included 110 male alcohol abusers showed that among the 49 who eventually maintained a year of abstinence, half developed 'substitute dependencies', including two who used cannabis (Vaillant et al., 1982). Though the above studies suggest that cannabis could be an alternative to alcohol, they are limited by small sample sizes, self-report and possible selection bias from medical cannabis patients. Furthermore, all studies besides Vaillant et al. (1982) rely on retrospective designs.

In addition, as discussed above, cannabis and alcohol can be considered complements in that combined use may lead to more substance use compared with the use of either alone (Bickel et al., 1995; Pacula, 1998; Midanik et al., 2007; Magill et al., 2009; Moore, 2010). In a large probability community survey of 733 at-risk drinkers, those who also used cannabis reported higher frequencies and quantities of alcohol use, as well as more negative alcohol-related consequences (Booth and Kirchner, 2001). Among 250 substance use disorder treatment seekers, cannabis use may have increased the hazard of alcohol relapse and decreased the likelihood of stable abstinence (Aharonovich et al., 2005).

Furthermore, the odds of alcohol dependence are substantially higher among those with cannabis dependence (Stinson et al., 2006), suggesting that hazardous alcohol use may increase as cannabis use increases. Similarly, the developmental literature shows that cannabis and alcohol use trajectories are related (Martin et al., 1996; Windle and Wiesner, 2004; Schulenberg et al., 2005; Pape et al., 2009), and that conjoint use can be explained by either common risk factors or the nature of the substances causing use of one to lead to use of the other (Jackson et al., 2008).

Thus, although a handful of studies claim that cannabis can substitute for alcohol, a number of others conclude that the two substances are complements: cannabis satisfies Criterion #4 only partially.

Criterion # 5: It Should Be Safer in Overdose Than Alcohol

As noted under Criterion #2, the safety ratio for cannabis is >10 times higher that of alcohol. Furthermore, the Substance Abuse and Mental Health Administration (SAMHSA) has explicitly stated: 'Cannabis is rarely the only drug involved in a drug abuse death… in most cases, the proportion of cannabis-involved cases labeled as "One drug" (i.e. cannabis only) will be zero or nearly zero'(Substance Abuse and Mental Health Services Administration, 2004). On the other hand, alcohol was deemed to be a cause of death for 3.5% of US mortalities in the year 2000 (Mokdad et al., 2004). This criterion is satisfied.

Criterion #6: It Should Ideally Not Potentiate the Effects of Alcohol Especially If Either Drug Is Taken in Overdose

The proportion of deaths attributed to cannabis alone has been documented as 'zero or nearly zero' in a report from SAMHSA, implying that it cannot be taken in overdose itself. Furthermore, combining cannabis with alcohol does not lead to higher blood or breath alcohol levels (Chait and Perry, 1994; Liguori et al., 2002). Although smoking cannabis may slow the absorption of ethanol, which subsequently reduces ethanol's psychoactive effects (Lukas et al., 1992), plasma THC levels can be enhanced if alcohol is consumed immediately after smoking cannabis (Lukas and Orozco, 2001; Downey et al., 2013). Thus cannabis combined with alcohol can lead to greater impairment than ingestion of either substance alone with the combination yielding additive (as opposed to multiplicative) effects on measures of impairment (Chait and Perry, 1994).

As noted in Ronen et al. (2010), the literature on combined cannabis/alcohol effects is small and with mixed results. While some studies have shown that combining cannabis and alcohol leads to greater impairment than either alone (Ramaekers et al., 2000, 2011; Bramness et al., 2010; Ronen et al., 2010; Downey et al., 2013), others have shown no differences (Liguori et al., 2002; Lenne et al., 2010; Ballard and de Wit, 2011). More recent studies have focused on the joint effects of cannabis and alcohol effects in regard to driving impairment. In a study of 18 healthy volunteers, Ramaekers et al. (2000) concluded that combining cannabis and alcohol impaired driving performance more than either alone. A 2010 study of 12 participants similarly showed that the combination of alcohol and cannabis had the strongest effects (compared with either substance alone) in terms of impaired (a) driving tasks, (b) non-driving tasks, such as arithmetic calculations, (c) subjective sensations, such as feeling 'high' or 'sedated' and (d) physiological measures, such as heart rate (Ronen et al., 2010). A similar, larger (n = 80) study of recreational cannabis and alcohol users also concluded that driving performance was worse for those under the influence of both cannabis and alcohol compared with either substance alone, and that THC-blood levels were higher for those who had consumed both substances (Downey et al., 2013).

Among heavy cannabis users, the joint effects of cannabis and alcohol were shown to impair divided attention (but not other neurocognitive tasks) more than alcohol alone (Ramaekers et al., 2011); importantly, these heavy users may have developed tolerance to cannabis that allowed them to perform better on these tasks than lighter users may perform. Furthermore, although the above driving simulation studies use double-blind, placebo-controlled designs, they were all rather small (n < 100), and not necessarily generalizable to heavy alcohol users. A larger (n = 5042), retrospective cross-sectional forensic database study of drivers apprehended for driving under the influence of alcohol showed that when THC and ethanol were both detected, the participant was more likely to be judged impaired; the risk of being judged impaired increased additively according to alcohol and cannabis dosages (Bramness et al., 2010).

Conversely, a number of other driving impairment studies have yielded divergent results. A study of joint alcohol and cannabis' effects on driving impairment, body sway and mood showed no additive effects of taking both substances (Liguori et al., 2002). A more recent study of 25 experienced and 22 inexperienced drivers similarly found no synergistic effects when combining alcohol and cannabis (Lenne et al., 2010). Another study of 11-healthy participants reported that the combination of cannabis and alcohol was not synergistic, and that the combination appeared to have less than additive effects on working memory, psychomotor ability and simple reaction time, or subjective mood compared with either substance alone (Ballard and de Wit, 2011). Although these studies may provide evidence that cannabis does not potentiate the effects of alcohol, these driving impairment studies are small and not generalizable to heavy drinkers per se.

Thus some studies have concluded that cannabis potentiates the effects of alcohol, while others report no synergistic or additive effects in terms of impairment. These divergent results may be due to differences in study designs (e.g. measures of impairment differed across studies). In light of the mixed evidence, cannabis only partially satisfies the sixth criterion. However, we could again compare alternative substitutes: benzodiazepines are known to exacerbate alcohol's effects, and the interaction between benzodiazepines and alcohol can be fatal (Koski et al., 2002).

Criterion #7: It Should Offer Significant Health Economic Benefits

From a strictly economic standpoint, the US Department of Justice states that in 1992, the total economic cost of alcohol abuse and alcoholism cost ~$148 billion, while drug abuse/dependence cost ~$98 billion (Harwood et al., 1998). This implies that the costs of cannabis on the aggregate level are probably much lower than the costs of alcohol. In terms of health care expenditures, the independent experts from Nutt et al. (2007) similarly ranked the costs of cannabis use lower than the costs of alcohol use (Nutt et al., 2007). However, these figures apply to the aggregate and do not necessarily mean that health economic benefits would be seen in individuals.

At the aggregate level, cannabis appears to satisfy Criterion #7. Yet because no studies to date have compared individual health economic outcomes for those who substitute cannabis versus those who do not, prospective studies of long-term drinking patterns, alcohol-related harms and problems and changes in quality of life are needed.

processing....